Note on the Experimental Transmission of Warts in the Dog

M'Fadyean, J.; Hobday, Frederick

doi:10.1016/s0368-1742(98)80056-8

Cited by 42 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One hundred years have passed since the first reports of transmissible warts in the dog were noted in this journal by its founder (M'Fadyean and Hobday, 1898;Penberthy, 1898). These early observations by M'Fadyean, Penberthy and Hobday started a line of enquiry leading to the development of efficient vaccines which may play a key role in the control of important animal and human diseases.…”

Section: Introductionmentioning

confidence: 99%

Canine Papillomavirus—A Centenary Review

Nicholls

Stanley

1999

Journal of Comparative Pathology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Canine Papillomavirus—A Centenary Review

Nicholls

Stanley

1999

Journal of Comparative Pathology

View full text Add to dashboard Cite

“…The relationship between viruses and cancer is a long story that started with studies showing that warts and cancers can be transmitted by cell-free extracts [1][2][3][4][5][6]. The role of many oncogenic viruses from diVerent RNA virus (retrovirus, Xavivirus) and DNA virus families (hepadnavirus, herpes virus, papovavirus) is very well established [5,6].…”

mentioning

confidence: 99%

“…In the meantime, many reports by numerous groups demonstrated oncomodulatory eVects exerted by HCMV or single cytomegalovirus proteins in vitro an in vivo [12]. Mechanisms involved in HCMV-induced oncomodulation may include eVects on cell proliferation, survival, invasion, immunogenicity, tumour angiogenesis, tumour proinXammatory state, cancer cell epigenetics, and chromosomal stability [1,19,[38][39][40].…”

mentioning

confidence: 99%

Oncomodulation by human cytomegalovirus: novel clinical findings open new roads

Michaelis

Baumgarten

Mittelbronn

et al. 2010

Med Microbiol Immunol

View full text Add to dashboard Cite

The question whether human cytomegalovirus may affect cancer diseases has been discussed (very controversially) for decades. There are convinced believers and strict opponents of the idea that HCMV might be able to play a role in the course of cancer diseases. In parallel, the number of published reports on the topic is growing. Recently published and presented (Ranganathan P, Clark P, Kuo JS, Salamat S, Kalejta RF. A Survey of Human Cytomegalovirus Genomic Loci Present in Glioblastoma Multiforme Tissue Samples. 35th Annual International Herpes Workshop, Salt Lake City, 2010) data on HCMV detection in glioblastoma tissues and colocalisation of HCMV proteins with cellular proteins known to be relevant for glioblastoma progression motivated us to recapitulate the current state of evidence.

show abstract

“…The development and deployment of human papillomavirus vaccines demonstrate the benefits of collaborative research activity across the globe, and between academia and industry, to translate scientific discoveries into public health benefits. The Journal of Immunology, 2014, 192: 4007-4011. A n association of viral infection with development of proliferative skin lesions in animals was recognized almost as soon as viruses were first described as filterable agents causing disease (1). Evidence for association of viral infection with specific cancers in humans took longer, as causality could not be tested according to Koch's postulates.…”

Section: Ian H Frazermentioning

confidence: 99%

Development and Implementation of Papillomavirus Prophylactic Vaccines

Frazer

2014

The Journal of Immunology

View full text Add to dashboard Cite

Translation of basic scientific findings into practical patient outcomes is a significant exercise even when the goal is conceptually straightforward, as in the development of a vaccine for an infectious disease. Recognition of the association of cervical cancer with papillomavirus infection encouraged development of a vaccine to help with prevention of this very common cancer, causing over 250,000 deaths each year worldwide. To introduce a vaccine program, it was however necessary to develop a technology for making viral Ag, demonstrate that systemic immunization could provide mucosal surface protection in the genital tract, develop assays for vaccine potency, and understand enough about the epidemiology and natural history of the infection to plan effective intervention strategies. This process took ∼25 years. The major hurdle, now that effective vaccines are available, is to ensure their deployment in the countries where they are most needed. The development and deployment of human papillomavirus vaccines demonstrate the benefits of collaborative research activity across the globe, and between academia and industry, to translate scientific discoveries into public health benefits.

show abstract

Note on the Experimental Transmission of Warts in the Dog

Cited by 42 publications

References 0 publications

Canine Papillomavirus—A Centenary Review

Canine Papillomavirus—A Centenary Review

Oncomodulation by human cytomegalovirus: novel clinical findings open new roads

Development and Implementation of Papillomavirus Prophylactic Vaccines

Contact Info

Product

Resources

About